Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4046-4051

  Barnhill, Alison E ^a   Brewer, Matt T ^a   Carlson, Steve A ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CHLORAMPHENICOL; DNA TOPOISOMERASE; EPEREZOLID; ERYTHROMYCIN; GENTAMICIN; IONOPHORE; ISONIAZID; KANAMYCIN; LINCOSAMIDE; LINEZOLID; METRONIDAZOLE; NEOMYCIN; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; TOBRAMYCIN;

ADVERSE OUTCOME; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; APLASTIC ANEMIA; BONE MARROW SUPPRESSION; CELL ORGANELLE; CHONDROTOXICITY; DISEASE TRANSMISSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSGLYCEMIA; EUKARYOTIC CELL; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERLACTATEMIA; INTESTINE MOTILITY; LACTIC ACIDOSIS; MITOCHONDRION; MYOPATHY; NEOPLASM; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROPATHY; OTOTOXICITY; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROKARYOTE; RETINOPATHY; RIBOSOME; SEROTONIN SYNDROME; SHORT SURVEY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXICITY;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CHLORAMPHENICOL; DNA TOPOISOMERASES, TYPE I; FLUOROQUINOLONES; HUMANS; MITOCHONDRIA; OXAZOLIDINONES; PROTEIN BIOSYNTHESIS; RIBOSOMES;

EID: 84864387245     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00678-12     Document Type: Short Survey

References (108)

1. Aspinall S, et al. 2009. Severe dysglycemia with the fluoroquinolones: a class effect? Clin. Infect. Dis. 49:402-408.
2. Attardi G, et al. 1977. Molecular and genetic approaches to the analysis of the informational content of the mitochondrial genome in mammalian cells. Mol. Cell. Biochem. 14:151-164.
3. Bai Y, et al. 2004. Genetic and functional analysis of mitochondrial DNA-encoded complex I genes. Ann. N. Y. Acad. Sci. 1011:272-283. (Pubitemid 38608411)
4. Best J, Marashi A, Pollan L. 1999. Neuromuscular blockade after clindamycin administration: a case report. J. Oral Maxillofac. Surg. 57:600-603. (Pubitemid 29214257)
5. Caldeira C, et al. 2001. Rhabdomyolysis, acute renal failure, and death after monensin ingestion. Am. J. Kidney Dis. 38:1108-1112. (Pubitemid 33022191)
6. Carter A, et al. 2000. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407:340-348.
7. Catnach S, Fairclough P. 1992. Erythromycin and the gut. Gut 33:397-401.
8. Chaplin S. 1986. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol. Adverse Drug React. Acute Poisoning Rev. 5:97-136. (Pubitemid 16064268)
9. Cruchaud A, Gfeller G, Hausser E. 1963. Blood dyscrasias due to chloramphenicol. Study of the pathogenic mechanisms. Schweiz. Med. Wochenschr. 93:1731-1735.
10. Cruchaud A, et al. 1963. 3 cases of blood disorders following the administration of chloramphenicol. Schweiz. Med. Wochenschr. 93:1471-1475.
11. Davenport C, Boston R, Richardson D. 2001. Effects of enrofloxacin and magnesium deficiency on matrix metabolism in equine articular cartilage. Am. J. Vet. Res. 62:160-166. (Pubitemid 32116386)
12. De Vriese A, et al. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 42:1111-1117.
13. Duewelhenke N, Krut O, Eysel P. 2007. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob. Agents Chemother. 51:54-63. (Pubitemid 46047687)
14. Feighner S, et al. 1999. Receptor for motilin identified in the human gastrointestinal system. Science 284:2184-2188. (Pubitemid 29297480)
15. Ferry T, et al. 2005. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 33:151-154. (Pubitemid 40881107)
16. Ford M, Dubielzig R, Giuliano E, Moore C, Narfström K. 2007. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am. J. Vet. Res. 68:190-202. (Pubitemid 46358698)
17. Forge A, Schacht J. 2000. Aminoglycoside antibiotics. Audiol. Neurootol. 5:3-22. (Pubitemid 30093591)
18. Forsythe C, Ernst M. 2007. Do fluoroquinolones commonly cause arthropathy in children? CJEM 9:459-462.
19. Friedman G, et al. 2009. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int. J. Cancer 125:2173-2178.
20. Fritsch P, Sidoroff A. 2000. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am. J. Clin. Dermatol. 1:349-360.
21. Garrabou G, et al. 2007. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob. Agents Chemother. 51:962-967. (Pubitemid 46355281)
22. Ge T, Law P, Wong H, Ho Y. 2007. Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. Eur. J. Pharmacol. 573:70-74. (Pubitemid 47464227)
23. Glode M. 1982. Commentary: what price orange urine? Pediatr. Infect. Dis. 1:140-141. (Pubitemid 13134998)
24. Gorchynski J, Rose J. 2008. Complications of MRSA treatment: linezolid-induced myelosuppression presenting with pancytopenia. West. J. Emerg. Med. 9:177-178.
25. Grishko V, et al. 2009. Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J. Biol. Chem. 284:9132-9139.
26. Grivell L, Walg H. 1972. Subunit homology between Escherichia coli, mitochondrial and chloroplast ribosomes. Biochem. Biophys. Res. Commun. 49:1452-1458.
27. Guthrie O. 2008. Aminoglycoside induced ototoxicity. Toxicology 249:91-96.
28. Hall J. 2001. Toxic feed constituents in the horse. Vet. Clin. North Am. Equine Pract. 17:479-489.
29. Hayem G, et al. 1994. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 38:243-247. (Pubitemid 24054241)
30. Hobson-Webb L, Roach E, Donofrio P. 2006. Metronidazole: newly recognized cause of autonomic neuropathy. J. Child Neurol. 21:429-431. (Pubitemid 44057065)
31. Holdiness M. 1989. A review of the Redman syndrome and rifampicin overdosage. Med. Toxicol. Adverse Drug Exp. 4:444-451. (Pubitemid 19264127)
32. International Agency for Research on Cancer. 1990. Chloramphenicol. IARC Monogr. Eval. Carcinog. Risks Chem. Hum. 50:169-193.
33. Javaheri M, Khurana R, O'Hearn T, Lai M, Sadun A. 2007. Linezolidinduced optic neuropathy: a mitochondrial disorder? Br. J. Ophthalmol. 91:111-115. (Pubitemid 46094021)
34. Johannes C, et al. 2007. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 30:705-713. (Pubitemid 47295830)
35. Johnson R, Cohen A, Guo Y, Schibler K, Greinwald J. 2010. Genetic mutations and aminoglycoside-induced ototoxicity in neonates. Otolaryngol. Head Neck Surg. 142:704-707.
36. Jones C, Miller C, Tenenbaum A, Spremulli L, Saada A. 2009. Antibiotic effects on mitochondrial translation and in patients with mitochondrial translational defects. Mitochondrion 9:429-437.
37. + overload, major and reversible contributors to weakness by ion channel leaks. Proc. Natl. Acad. Sci. U. S. A. 106:4036-4041.
38. Kaloyanides G. 1992. Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity. Ren. Fail. 14:351-357.
39. Kim H, et al. 2008. Mitochondrial DNA aberrations of bone marrow cells from patients with aplastic anemia. J. Korean Med. Sci. 23:1062-1067.
40. Kondo J, Westhof E. 2008. The bacterial and mitochondrial ribosomal A-site molecular switches possess different conformational substates. Nucleic Acids Res. 36:2654-2666. (Pubitemid 351659579)
41. Krakoff IH, Karnofsky DA, Burchenal JH. 1955. Effects of large doses of chloramphenicol on human subjects. N. Engl. J. Med. 253:7-10.
42. Laferriere C, Marks M. 1982. Chloramphenicol: properties and clinical use. Pediatr. Infect. Dis. 1:257-264. (Pubitemid 13136438)
43. Langlois M, Derk F, Belczyk R, Zgonis T. 2010. Trimethoprimsulfamethoxazole-induced Stevens-Johnson syndrome: a case report. J. Am. Podiatr. Med. Assoc. 100:299-303.
44. Lankerani L, Baron E. 2004. Photosensitivity to exogenous agents. J. Cutan. Med. Surg. 8:424-431. (Pubitemid 41414111)
45. Lannigan B, Evans D. 1982. The effect of minocycline on potassium leakage from red cells: a study of the genetics and relationship to vestibular adverse reactions. J. Med. Genet. 19:354-359. (Pubitemid 12037591)
46. Lawrence J, Claire D, Weissig V, Rowe T. 1996. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol. Pharmacol. 50:1178-1188. (Pubitemid 26384856)
47. Lazarus G, Henrich J, Kelly W, Schmitz S, Castora F. 1987. Purification and characterization of a type I DNA topoisomerase from calf thymus mitochondria. Biochemistry 26:6195-6203.
48. Lee S, Lee J, Lee S, Lee J, Lee J. 2008. Calcium and neostigmine antagonize gentamicin, but augment clindamycin-induced tetanic fade in rat phrenic nerve-hemidiaphragm preparations. J. Anesth. 22:385-390.
49. Leibovitz E. 2006. The use of fluoroquinolones in children. Curr. Opin. Pediatr. 18:64-70. (Pubitemid 43790891)
50. Leiter L, et al. 1999. Chloramphenicol-induced mitochondrial dysfunction is associated with decreased transferrin receptor expression and ferritin synthesis in K562 cells and is unrelated to IRE-IRP interactions. J. Cell. Physiol. 180:334-344. (Pubitemid 29334834)
51. Li Q, Peng S, Sheng Z, Wang Y. 2010. Ofloxacin induces oxidative damage to joint chondrocytes of juvenile rabbits: excessive production of reactive oxygen species, lipid peroxidation and DNA damage. Eur. J. Pharmacol. 626:146-153.
52. Livermore D. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl 2):9-16.
53. Luft F. 1978. Netilmicin: a review of toxicity in laboratory animals. J. Int. Med. Res. 6:286-299. (Pubitemid 8385596)
54. Malik M, Zhao X, Drlica K. 2006. Lethal fragmentation of bacterial chromosomes mediated byDNAgyrase and quinolones. Mol. Microbiol. 61:810-825. (Pubitemid 44324102)
55. McKee E, Ferguson M, Bentley A, Marks T. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50:2042-2049. (Pubitemid 43807524)
56. Mehta A, Vulliamy T, Gordon-Smith E, Luzzatto L. 1989. A new genetic polymorphism in the 16S ribosomal RNA gene of human mitochondrial DNA. Ann. Hum. Genet. 53:303-310. (Pubitemid 19282103)
57. Mitchell J, et al. 1975. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther. 18:70-79.
58. Moore P, Steitz T. 2011. The roles of RNA in the synthesis of protein. Cold Spring Harb. Perspect. Biol. 3:a003780. doi:10.1101/cshperspect.a003780.
59. Nagao T, Mauer A. 1969. Concordance for drug-induced aplastic anaemia in identical twins. N. Engl. J. Med. 281:7-11.
60. Nagiec EE, et al. 2005. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother. 49:3896-3902. (Pubitemid 41233047)
61. Narita M, Tsuji B, Yu V. 2007. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27:1189-1197. (Pubitemid 47173662)
62. Palomar GV, Abdulghani MF, Bodet AE, Andreu ML, Palomar AV. 2001. Drug-induced otoxicity: current status. Acta Otolaryngol. 121:569-572.
63. Pannu N, Nadim M. 2008. An overview of drug-induced acute kidney injury. Crit. Care Med. 36(4 Suppl):S216-S223. (Pubitemid 351483055)
64. Parsons T, Obaid A, Salzberg B. 1992. Aminoglycoside antibiotics block voltage-dependent calcium channels in intact vertebrate nerve terminals. J. Gen. Physiol. 99:491-504.
65. Pasquale T, Tan J. 2005. Nonantimicrobial effects of antibacterial agents. Clin. Infect. Dis. 40:127-135. (Pubitemid 40053470)
66. Pfister K, Mazur D, Vormann J, Stahlmann R. 2007. Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. Antimicrob. Agents Chemother. 51:1022-1027. (Pubitemid 46355290)
67. Pilot M, Ritchie H, Thompson H, Zara G. 1984. Alterations in gastrointestinal motility associated with erythromycin. Br. J. Pharmacol. 81:168.
68. Ponka P. 1997. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89:1-25. (Pubitemid 26428173)
69. Pouzaud F, et al. 2006. Age-dependent effects on redox status, oxidative stress, mitochondrial activity and toxicity induced by fluoroquinolones on primary cultures of rabbit tendon cells. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 143:232-241.
70. Prior C, et al. 1990. End-plate ion channel block produced by lincosamide antibiotics and their chemical analogs. J. Pharmacol. Exp. Ther. 255:1170-1176.
71. Riesbeck K, Bredberg A, Forsgren A. 1990. Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob. Agents Chemother. 34:167-169. (Pubitemid 20019986)
72. Robles M, Andrade R. 2008. Hepatotoxicity by antibiotics: update in 2008. Rev. Esp. Quimioter. 21:224-233.
73. Rougier F, Claude D, Maurin M, Maire P. 2004. Aminoglycoside nephrotoxicity. Curr. Drug Targets Infect. Disord. 4:153-162. (Pubitemid 38786652)
74. Roujeau J, et al. 1995. Medication use and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. N. Engl. J. Med. 333:1600-1606.
75. Rozza D, Vervuert I, Kamphues J, da Cruz C, Driemeier D. 2006. Monensin toxicosis in water buffaloes (Bubalus bubalis). J. Vet. Diagn. Invest. 18:494-496. (Pubitemid 44523653)
76. Rubin D, Weisberger A, Botti R, Storaasli J. 1958. Changes in iron metabolism in early chloramphenicol toxicity. J. Clin. Invest. 37:1286-1292.
77. Sánchez A, Rogers RI, Sheridan P. 2004. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int. J. Dermatol. 43:709-715. (Pubitemid 39405851)
78. Sasaki M, Miyazaki Y, Takahashi T. 2003. Hylan G-F 20 induces delayed foreign body inflammation in guinea pigs and rabbits. Toxicol. Pathol. 31:321-325. (Pubitemid 36597266)
79. Schwachman H, Schuster A. 1956. The tetracyclines: applied pharmacology. Pediatr. Clin. North Am. 3:295-303.
80. Scott J, Finegold S, Belkin G, Lawrence J. 1965. A controlled doubleblind study of the hematologic toxicity of chloramphenicol. N. Engl. J. Med. 272:1137-1142.
81. See S, Mumford J. 2001. Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann. Pharmacother. 35:694-697.
82. Seeger J, et al. 2006. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol. Drug Saf. 15:784-792. (Pubitemid 44762709)
83. Selimoglu E. 2007. Aminoglycoside-induced ototoxicity. Curr. Pharm. Des. 13:119-126. (Pubitemid 46085303)
84. Sendzik J, Lode H, Stahlmann R. 2009. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int. J. Antimicrob. Agents 33:194-200.
85. Simonin M, et al. 1999. Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice. Antimicrob. Agents Chemother. 43:2915-2921.
86. Skolimowski I, Knight R, Edwards D. 1983. Molecular basis of chloramphenicol and thiamphenicol toxicity to DNA in vitro. J. Antimicrob. Chemother. 12:535-542. (Pubitemid 14213176)
87. Soriano A, Miro O, Mensa J. 2005. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353:2305-2306.
88. Stahlmann R, et al. 1998. Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. Antimicrob. Agents Chemother. 42:1470-1475. (Pubitemid 28257652)
89. Sun F, Chen Y, Xiang Y, Zhan S. 2008. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int. J. Tuberc. Lung Dis. 12:994-1002.
90. Taketani T, et al. 2009. Pure red cell precursor toxicity by linezolid in a pediatric case. J. Pediatr. Hematol. Oncol. 31:684-686.
91. Trevett A, Naraqi S. 1992. Saint or sinner? A look at chloramphenicol. P. N. G. Med. J. 35:210-216.
92. Turton J, Fagg R, Sones W, Williams T, Andrews C. 2006. Characterization of the myelotoxicity of chloramphenicol succinate in the B6C3F1 mouse. Int. J. Exp. Pathol. 87:101-112.
93. Velissariou I. 2006. The use of fluoroquinolones in children: recent advances. Expert Rev. Anti Infect. Ther. 4:853-860. (Pubitemid 44890623)
94. Walker P, Barri Y, Shah S. 1999. Oxidant mechanisms in gentamicin nephrotoxicity. Ren. Fail. 21:433-442. (Pubitemid 29318213)
95. Wiebe V, Hamilton P. 2002. Fluoroquinolone-induced retinal degeneration in cats. J. Am. Vet. Med. Assoc. 221:1568-1571. (Pubitemid 35388095)
96. Wilhelm JM, Jessop JJ, Pettit SE. 1978. Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells. Biochemistry 17:1149-1153. (Pubitemid 8330707)
97. Wilhelm JM, Pettit SE, Jessop JJ. 1978. Aminoglycoside antibiotics and eukaryotic protein synthesis: structure-function relationships in the stimulation of misreading with a wheat embryo system. Biochemistry 17:1143-1149.
98. Woodruff B, Wijdicks E, Marshall W. 2002. Reversible metronidazole- induced lesions of the cerebellar dentate nuclei. N. Engl. J. Med. 346:68-69. (Pubitemid 34438927)
99. World Health Organization. 1988. Chloramphenicol. In Toxicological evaluation of certain veterinary drug residues in food. WHO food additives series 23. World Health Organization, Geneva, Switzerland.
100. Wurtz B. 1986. CVMA opposes chloramphenicol ban. CMAJ 135:105.
101. Yoon J, Brooks RJ, Zhao J, Isaacs D, Halper J. 2004. The effects of enrofloxacin on decorin and glycosaminoglycans in avian tendon cell cultures. Arch. Toxicol. 78:599-608.
102. Young NS, Alter BP. 1994. Aplastic anaemia: acquired and inherited. WB Saunders, Philadelphia, PA.
103. Yunis A. 1978. Drug-induced bone marrow aplasia. Rev. Bras. Pesqui. Med. Biol. 11:287-295.
104. Yunis A, Bloomberg G. 1964. Chloramphenicol toxicity: clinical features and pathogenesis. Prog. Hematol. 4:138-159.
105. Zhao B, et al. 2010. Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics. Photochem. Photobiol. 86:798-805.
106. Zhou S. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 9:310-312.
107. Zivkovic S, Lacomis D, Giuliani M. 2001. Sensory neuropathy associated with metronidazole: report of four cases and review of the literature. J. Clin. Neuromuscul. Dis. 3:8-12. (Pubitemid 32894451)
108. Zorov D. 2010. Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria. Kidney Int. 77:841-843.